Searching. Please wait…
1582
37
170
29108
4409
2600
347
389
Abstract: Background: The clinical benefits of the common off-label use of cytomegalovirus (CMV)-specific immunoglobulin (CMV-Ig) combined with antivirals in organ transplantation have not been previously assessed. The objective was to compare the risk of CMV infection and other post-transplantation outcomes between two CMV-Ig prophylaxis regimens in lung transplant recipients; Methods: Retrospective study of 124 donor CMV positive/recipient negative (D+/R?) patients receiving preventive ganciclovir/valganciclovir for 12 months, of whom 62 received adjunctive CMV-Ig as per label indication (short regimen [SR-Ig]; i.e., 7 doses over 2.5 months) and were compared to 62 who received an extended off-label regimen (ER-Ig) consisting of 17 doses over one year after transplantation. Results: The incidence of CMV infection or disease, acute rejection, chronic lung allograft dysfunction, and survival did not differ between the two CMV-Ig schedules. Although the time to the first CMV infection after transplantation was shorter in the ER-Ig than in the SR-Ig adjunctive group (log-rank: p = 0.002), the risk was independently predicted by antiviral cessation (odds ratio = 3.74; 95% confidence interval = 1.04?13.51; p = 0.030), whereas the CMV-Ig schedule had no effect. Conclusions: Extending the adjunctive CMV-Ig prophylaxis beyond the manufacturer's recommendations up to one year does not confer additional clinical benefits regarding lung post-transplantation outcomes.
Fuente: Microorganisms, 2023, 11, 32
Publisher: MDPI
Year of publication: 2023
No. of pages: 14
Publication type: Article
DOI: 10.3390/microorganisms11010032
ISSN: 2076-2607
Publication Url: https://doi.org/10.3390/microorganisms11010032
Consult in UCrea Read publication
VÍCTOR MANUEL MORA CUESTA
USSETTI, PIEDAD
PABLO, ALICIA DE
DAVID ITURBE FERNANDEZ
LAPORTA, ROSALÍA
ALONSO, RODRIGO
AGUILAR, MYRIAM
QUEZADA, CARLOS A.
JOSE MANUEL CIFRIAN MARTINEZ
Back